Axillary  ||| S:0 E:9 ||| JJ
basal  ||| S:9 E:15 ||| JJ
cell  ||| S:15 E:20 ||| NN
carcinoma--a  ||| S:20 E:33 ||| JJ
rare  ||| S:33 E:38 ||| JJ
form  ||| S:38 E:43 ||| NN
of  ||| S:43 E:46 ||| IN
a  ||| S:46 E:48 ||| DT
frequent  ||| S:48 E:57 ||| JJ
kind  ||| S:57 E:62 ||| NN
of  ||| S:62 E:65 ||| IN
carcinoma  ||| S:65 E:75 ||| FW
Basal  ||| S:75 E:81 ||| FW
cell  ||| S:81 E:86 ||| FW
carcinoma  ||| S:86 E:96 ||| FW
( ||| S:96 E:97 ||| -LRB-
BCC ||| S:97 E:100 ||| NNP
)  ||| S:100 E:102 ||| -RRB-
is  ||| S:102 E:105 ||| VBZ
the  ||| S:105 E:109 ||| DT
most  ||| S:109 E:114 ||| RBS
common  ||| S:114 E:121 ||| JJ
cutaneous  ||| S:121 E:131 ||| JJ
cancer ||| S:131 E:137 ||| NN
.  ||| S:137 E:139 ||| .
It  ||| S:139 E:142 ||| PRP
seems  ||| S:142 E:148 ||| VBZ
that  ||| S:148 E:153 ||| IN
the  ||| S:153 E:157 ||| DT
most  ||| S:157 E:162 ||| RBS
important  ||| S:162 E:172 ||| JJ
prognostic  ||| S:172 E:183 ||| JJ
factor  ||| S:183 E:190 ||| NN
is  ||| S:190 E:193 ||| VBZ
exposure  ||| S:193 E:202 ||| NN
to  ||| S:202 E:205 ||| TO
ultraviolet  ||| S:205 E:217 ||| VB
radiation  ||| S:217 E:227 ||| NN
( ||| S:227 E:228 ||| -LRB-
solar  ||| S:228 E:234 ||| JJ
and  ||| S:234 E:238 ||| CC
artificial ||| S:238 E:248 ||| JJ
) ||| S:248 E:249 ||| -RRB-
,  ||| S:249 E:251 ||| ,
correlated  ||| S:251 E:262 ||| VBG
with  ||| S:262 E:267 ||| IN
other  ||| S:267 E:273 ||| JJ
factors  ||| S:273 E:281 ||| NNS
as  ||| S:281 E:284 ||| IN
well ||| S:284 E:288 ||| RB
.  ||| S:288 E:290 ||| .
In  ||| S:290 E:293 ||| IN
this  ||| S:293 E:298 ||| DT
article ||| S:298 E:305 ||| NN
,  ||| S:305 E:307 ||| ,
we  ||| S:307 E:310 ||| PRP
aimed  ||| S:310 E:316 ||| VBD
to  ||| S:316 E:319 ||| TO
review  ||| S:319 E:326 ||| VB
basal  ||| S:326 E:332 ||| JJ
cell  ||| S:332 E:337 ||| NN
carcinoma  ||| S:337 E:347 ||| VBZ
located  ||| S:347 E:355 ||| VBN
in  ||| S:355 E:358 ||| IN
the  ||| S:358 E:362 ||| DT
axilla ||| S:362 E:368 ||| NN
,  ||| S:368 E:370 ||| ,
referring  ||| S:370 E:380 ||| VBG
to  ||| S:380 E:383 ||| TO
cases  ||| S:383 E:389 ||| NNS
from  ||| S:389 E:394 ||| IN
our  ||| S:394 E:398 ||| PRP$
hospital ||| S:398 E:406 ||| NN
.  ||| S:406 E:408 ||| .
Axillary  ||| S:408 E:417 ||| JJ
location  ||| S:417 E:426 ||| NN
of  ||| S:426 E:429 ||| IN
BCC  ||| S:429 E:433 ||| NNP
is  ||| S:433 E:436 ||| VBZ
rare ||| S:436 E:440 ||| JJ
,  ||| S:440 E:442 ||| ,
with  ||| S:442 E:447 ||| IN
a  ||| S:447 E:449 ||| DT
very  ||| S:449 E:454 ||| RB
low  ||| S:454 E:458 ||| JJ
number  ||| S:458 E:465 ||| NN
of  ||| S:465 E:468 ||| IN
cases  ||| S:468 E:474 ||| NNS
quoted  ||| S:474 E:481 ||| VBN
in  ||| S:481 E:484 ||| IN
the  ||| S:484 E:488 ||| DT
literature ||| S:488 E:498 ||| NN
,  ||| S:498 E:500 ||| ,
compared  ||| S:500 E:509 ||| VBN
to  ||| S:509 E:512 ||| TO
the  ||| S:512 E:516 ||| DT
high  ||| S:516 E:521 ||| JJ
prevalence  ||| S:521 E:532 ||| NN
of  ||| S:532 E:535 ||| IN
basal  ||| S:535 E:541 ||| JJ
cell  ||| S:541 E:546 ||| NN
carcinoma  ||| S:546 E:556 ||| NN
in  ||| S:556 E:559 ||| IN
the  ||| S:559 E:563 ||| DT
general  ||| S:563 E:571 ||| JJ
population ||| S:571 E:581 ||| NN
.  ||| S:581 E:583 ||| .
During  ||| S:583 E:590 ||| IN
a  ||| S:590 E:592 ||| DT
period  ||| S:592 E:599 ||| NN
of  ||| S:599 E:602 ||| IN
two  ||| S:602 E:606 ||| CD
years ||| S:606 E:611 ||| NNS
,  ||| S:611 E:613 ||| ,
we  ||| S:613 E:616 ||| PRP
detected  ||| S:616 E:625 ||| VBD
only  ||| S:625 E:630 ||| RB
four  ||| S:630 E:635 ||| CD
cases  ||| S:635 E:641 ||| NNS
of  ||| S:641 E:644 ||| IN
axillary  ||| S:644 E:653 ||| JJ
basal  ||| S:653 E:659 ||| JJ
cell  ||| S:659 E:664 ||| NN
carcinoma  ||| S:664 E:674 ||| VBD
out  ||| S:674 E:678 ||| RP
of  ||| S:678 E:681 ||| IN
a  ||| S:681 E:683 ||| DT
total  ||| S:683 E:689 ||| JJ
number  ||| S:689 E:696 ||| NN
of  ||| S:696 E:699 ||| IN
921  ||| S:699 E:703 ||| CD
cases  ||| S:703 E:709 ||| NNS
diagnosed  ||| S:709 E:719 ||| VBN
as  ||| S:719 E:722 ||| IN
BCC ||| S:722 E:725 ||| NNP
.  ||| S:725 E:727 ||| .
We  ||| S:727 E:730 ||| PRP
were  ||| S:730 E:735 ||| VBD
interested  ||| S:735 E:746 ||| VBN
in  ||| S:746 E:749 ||| IN
identifying  ||| S:749 E:761 ||| VBG
certain  ||| S:761 E:769 ||| JJ
factors  ||| S:769 E:777 ||| NNS
involved  ||| S:777 E:786 ||| VBN
in  ||| S:786 E:789 ||| IN
causing  ||| S:789 E:797 ||| VBG
BCC ||| S:797 E:800 ||| NNP
,  ||| S:800 E:802 ||| ,
post-excision  ||| S:802 E:816 ||| JJ
clinical  ||| S:816 E:825 ||| JJ
evolution ||| S:825 E:834 ||| NN
,  ||| S:834 E:836 ||| ,
histological  ||| S:836 E:849 ||| JJ
type  ||| S:849 E:854 ||| NN
and  ||| S:854 E:858 ||| CC
aggressiveness  ||| S:858 E:873 ||| NN
of  ||| S:873 E:876 ||| IN
axillary  ||| S:876 E:885 ||| JJ
basal  ||| S:885 E:891 ||| JJ
cell  ||| S:891 E:896 ||| NN
carcinoma ||| S:896 E:905 ||| NN
.  ||| S:905 E:907 ||| .
Therefore ||| S:907 E:916 ||| RB
,  ||| S:916 E:918 ||| ,
we  ||| S:918 E:921 ||| PRP
quantified  ||| S:921 E:932 ||| VBP
objectively  ||| S:932 E:944 ||| RB
the  ||| S:944 E:948 ||| DT
tumor  ||| S:948 E:954 ||| NN
and  ||| S:954 E:958 ||| CC
stromal  ||| S:958 E:966 ||| JJ
expression  ||| S:966 E:977 ||| NN
of  ||| S:977 E:980 ||| IN
some  ||| S:980 E:985 ||| DT
immunological  ||| S:985 E:999 ||| JJ
markers  ||| S:999 E:1007 ||| NN
like ||| S:1007 E:1011 ||| IN
:  ||| S:1011 E:1013 ||| :
metalloproteinases  ||| S:1013 E:1032 ||| CD
MMP1 ||| S:1032 E:1036 ||| CD
,  ||| S:1036 E:1038 ||| ,
3 ||| S:1038 E:1039 ||| CD
,  ||| S:1039 E:1041 ||| ,
11 ||| S:1041 E:1043 ||| CD
,  ||| S:1043 E:1045 ||| ,
Ber-EP4  ||| S:1045 E:1053 ||| NNP
and  ||| S:1053 E:1057 ||| CC
Ki67 ||| S:1057 E:1061 ||| NNP
.  ||| S:1061 E:1063 ||| .
Histological  ||| S:1063 E:1076 ||| JJ
types  ||| S:1076 E:1082 ||| NNS
of  ||| S:1082 E:1085 ||| IN
tumors  ||| S:1085 E:1092 ||| NNS
investigated  ||| S:1092 E:1105 ||| VBD
here  ||| S:1105 E:1110 ||| RB
belong  ||| S:1110 E:1117 ||| VB
to  ||| S:1117 E:1120 ||| TO
the  ||| S:1120 E:1124 ||| DT
category  ||| S:1124 E:1133 ||| NN
of  ||| S:1133 E:1136 ||| IN
non-aggressive  ||| S:1136 E:1151 ||| NNP
BCC ||| S:1151 E:1154 ||| NNP
,  ||| S:1154 E:1156 ||| ,
namely  ||| S:1156 E:1163 ||| RB
as  ||| S:1163 E:1166 ||| IN
nodular  ||| S:1166 E:1174 ||| NN
and  ||| S:1174 E:1178 ||| CC
superficial ||| S:1178 E:1189 ||| JJ
,  ||| S:1189 E:1191 ||| ,
although  ||| S:1191 E:1200 ||| IN
Ki67  ||| S:1200 E:1205 ||| CD
index  ||| S:1205 E:1211 ||| NN
is  ||| S:1211 E:1214 ||| VBZ
greater  ||| S:1214 E:1222 ||| JJR
than  ||| S:1222 E:1227 ||| IN
the  ||| S:1227 E:1231 ||| DT
average  ||| S:1231 E:1239 ||| NN
reported  ||| S:1239 E:1248 ||| VBD
in  ||| S:1248 E:1251 ||| IN
the  ||| S:1251 E:1255 ||| DT
literature  ||| S:1255 E:1266 ||| NN
for  ||| S:1266 E:1270 ||| IN
this  ||| S:1270 E:1275 ||| DT
type  ||| S:1275 E:1280 ||| NN
of  ||| S:1280 E:1283 ||| IN
tumor ||| S:1283 E:1288 ||| NN
.  ||| S:1288 E:1290 ||| .
MMPs  ||| S:1290 E:1295 ||| JJ
exhibited  ||| S:1295 E:1305 ||| NN
increased  ||| S:1305 E:1315 ||| VBD
expression  ||| S:1315 E:1326 ||| NN
in  ||| S:1326 E:1329 ||| IN
tumors  ||| S:1329 E:1336 ||| NNS
and  ||| S:1336 E:1340 ||| CC
stromal  ||| S:1340 E:1348 ||| JJ
compartments ||| S:1348 E:1360 ||| NN
,  ||| S:1360 E:1362 ||| ,
especially  ||| S:1362 E:1373 ||| RB
at  ||| S:1373 E:1376 ||| IN
the  ||| S:1376 E:1380 ||| DT
tumor  ||| S:1380 E:1386 ||| NN
invasion  ||| S:1386 E:1395 ||| NN
front ||| S:1395 E:1400 ||| NN
,  ||| S:1400 E:1402 ||| ,
and  ||| S:1402 E:1406 ||| CC
was  ||| S:1406 E:1410 ||| VBD
not  ||| S:1410 E:1414 ||| RB
associated  ||| S:1414 E:1425 ||| VBN
with  ||| S:1425 E:1430 ||| IN
tumor  ||| S:1430 E:1436 ||| NN
ulceration  ||| S:1436 E:1447 ||| NNS
or  ||| S:1447 E:1450 ||| CC
surrounding  ||| S:1450 E:1462 ||| VBG
tissue  ||| S:1462 E:1469 ||| NN
remodeling-related  ||| S:1469 E:1488 ||| JJ
changes ||| S:1488 E:1495 ||| NNS
.  ||| S:1495 E:1497 ||| .
Our  ||| S:1497 E:1501 ||| PRP$
results  ||| S:1501 E:1509 ||| NNS
confirm  ||| S:1509 E:1517 ||| VBP
the  ||| S:1517 E:1521 ||| DT
literature  ||| S:1521 E:1532 ||| NN
data  ||| S:1532 E:1537 ||| NNS
concerning  ||| S:1537 E:1548 ||| VBG
the  ||| S:1548 E:1552 ||| DT
involvement  ||| S:1552 E:1564 ||| NN
of  ||| S:1564 E:1567 ||| IN
MMPs  ||| S:1567 E:1572 ||| JJ
in  ||| S:1572 E:1575 ||| IN
BCC  ||| S:1575 E:1579 ||| NNP
progression ||| S:1579 E:1590 ||| NN
,  ||| S:1590 E:1592 ||| ,
whatever  ||| S:1592 E:1601 ||| WDT
the  ||| S:1601 E:1605 ||| DT
tumor  ||| S:1605 E:1611 ||| NN
location  ||| S:1611 E:1620 ||| NN
is ||| S:1620 E:1622 ||| VBZ
.  ||| S:1622 E:1624 ||| .
